Alexion Pharmaceuticals Filed Reply in Antitrust Case
The company seeks a judgment on the pleadings in an ongoing lawsuit regarding competition for its drug Soliris.
Updated on Sept. 21, 2026 in Healthcare
Alexion Pharmaceuticals has filed a reply in support of its motion for judgment on pleadings as part of an antitrust suit. EmblemHealth originally sued the company, alleging that it improperly delayed biosimilar competition for Soliris.
Why it matters
Alexion Pharmaceuticals argues that the plaintiff lacks standing to bring its sham litigation claims. This case centers on whether the pharmaceutical giant improperly leveraged alleged fraud on the Patent and Trademark Office to maintain market dominance.
This official filing follows a prior court determination that specific allegations of fraud on the Patent and Trademark Office were too far removed from the plaintiff's claimed injuries. The case remains open as the court weighs the merits of the antitrust allegations.
The players
Alexion Pharmaceuticals
This pharmaceutical company specializes in developing life-transforming therapies for patients with rare diseases.
EmblemHealth
This organization is one of the largest non-profit health insurers in the United States.
The details
EmblemHealth claims that Alexion Pharmaceuticals engaged in conduct designed to stifle biosimilar competition for Soliris, which is used to treat rare blood and immune disorders. Alexion maintains that the lawsuit fails to meet legal standards for establishing standing in a sham litigation challenge.
Timeline
September 21, 2026: Alexion Pharmaceuticals filed the reply in support of its motion.
Market Landscape
This case follows the pattern of complex pharmaceutical antitrust litigation where plaintiffs target alleged abuses of the patent system to extend market exclusivity. These legal battles frequently reshape competition dynamics in the high-cost specialty drug market.
The outcome of this antitrust litigation could influence the availability and cost of biosimilar treatments for rare disorders. Consumers and healthcare providers should monitor the case for potential shifts in the competitive landscape for essential specialty medications.
The takeaway
This case highlights the ongoing friction between patent protection strategies and efforts to introduce more affordable biosimilar competition. Legal decisions in this space often dictate how quickly lower-cost alternatives reach patients reliant on expensive specialty drugs.
Further reading
For more on industry litigation trends, visit the United States Healthcare section.
